0000914475-24-000009.txt : 20240110
0000914475-24-000009.hdr.sgml : 20240110
20240110163124
ACCESSION NUMBER: 0000914475-24-000009
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240108
FILED AS OF DATE: 20240110
DATE AS OF CHANGE: 20240110
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GORMAN KEVIN CHARLES
CENTRAL INDEX KEY: 0001201096
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22705
FILM NUMBER: 24526940
MAIL ADDRESS:
STREET 1: 12790 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC
CENTRAL INDEX KEY: 0000914475
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 330525145
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 617-7600
MAIL ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
wk-form4_1704922274.xml
FORM 4
X0508
4
2024-01-08
0
0000914475
NEUROCRINE BIOSCIENCES INC
NBIX
0001201096
GORMAN KEVIN CHARLES
12780 EL CAMINO REAL
SAN DIEGO
CA
92130
1
1
0
0
Chief Executive Officer
1
Common Stock
2024-01-08
4
M
0
105835
19.59
A
605589
D
Common Stock
2024-01-08
4
S
0
105835
132.4375
D
499754
D
Common Stock
2024-01-09
4
M
0
62023
19.59
A
561777
D
Common Stock
2024-01-09
4
S
0
62023
134.0131
D
499754
D
Non-Qualified Stock Option
19.59
2024-01-08
4
M
0
105835
19.59
D
2024-01-16
Common Stock
105835
62023
D
Non-Qualified Stock Option
19.59
2024-01-09
4
M
0
62023
19.59
D
2024-01-16
Common Stock
62023
0
D
The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 22, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.72 to $133.94. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.28 to $134.88. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
491,365 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power.
The option was granted January 16, 2014 and vested in 48 equal monthly installments beginning February 16, 2014. These options will expire ten years from the date of grant on January 16, 2024.
/s/ Darin Lippoldt, Attorney-in-Fact
2024-01-10